VRCAVerrica Pharmaceuticals Inc.Signing up patients
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Common Warts · Common Warts (Verruca Vulgaris) · Human Papilloma Virus (HPV) · Warts
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 300 (planned)
- Started
- Jun 15, 2026
- Main results expected
- May 2027
- Fully finished
- Jul 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.
Measured over: Day 84 (0/+8 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07637734 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC